COMPONENTS OF A MOTIVE TO SUCCEEDFISHER R. I.JOURNAL (THE) OF EXPERIMENTAL EDUCATION. 1973, Vol 41, Num 3, pp 17-21Article

A STUDY OF NON-INTELLECTUAL ATTRIBUTES OF CHILDREN IN FIRST GRADE BILINGUAL-BICULTURAL PROGRAMFISHER R. I.JOURNAL OF EDUCATIONAL RESEARCH. 1974, Vol 67, Num 7, pp 323-329Article

Current trends in large cell lymphomaFISHER, R. I; SHAH, P.Leukemia. 2003, Vol 17, Num 10, pp 1948-1960, issn 0887-6924, 13 p.Article

Bortezomib in patients with relapsed or refractory mantle cell lymphoma : updated time-to-event analyses of the multicenter phase 2 PINNACLE studyGOY, A; BERNSTEIN, S. H; NASTA, S et al.Annals of oncology. 2009, Vol 20, Num 3, pp 520-525, issn 0923-7534, 6 p.Article

Outpatient biochemotherapy with interleukin-2 and interferon alfa-2b in patients with metastatic malignant melanoma: results of two phase II Cytokine Working Group trialsFLAHERTY, L. E; ATKINS, M; SOROKIN, P et al.Journal of clinical oncology. 2001, Vol 19, Num 13, pp 3194-3202, issn 0732-183XArticle

Diffuse large-cell lymphomaFISHER, R. I.Annals of oncology. 2000, Vol 11, pp 29-33, issn 0923-7534, SUP1Conference Paper

Lymphoma classification : The gap between biology and clinical management is closingHIDDEMANN, W; LONGO, D. L; COIFFIER, B et al.Blood. 1996, Vol 88, Num 11, pp 4085-4089, issn 0006-4971Article

Phase II studies of recombinant human interleukin-4 in advanced renal cancer and malignant melanomaMARGOLIN, K; ARONSON, F. R; DUTCHER, J. P et al.Journal of immunotherapy. 1994, Vol 15, Num 2, pp 147-153, issn 1053-8550Article

Phase II trials of high-dose interleukin-2 and lymphokine-activated killer cells in advanced breast carcinoma and carcinoma of the lung, ovary, and pancreas and other tumorsSPARANO, J. A; FISHER, R. I; DOROSHOW, J. H et al.Journal of immunotherapy. 1994, Vol 16, Num 3, pp 216-223, issn 1053-8550Conference Paper

Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanomaSPARANO, J. A; FISHER, R. I; DOROSHOW, J. H et al.Journal of clinical oncology. 1993, Vol 11, Num 10, pp 1969-1977, issn 0732-183XArticle

Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipientsSWINNEN, L. J; COSTANZO-NORDIN, M. R; FISHER, S. G et al.The New England journal of medicine. 1990, Vol 323, Num 25, pp 1723-1728, issn 0028-4793Article

Appearance and phenotypic characterization of circulating Leu 19+ cells in cancer patients receiving recombinant interleukin 2ELLIS, T. M; CREEKMORE, S. P; MCMANNIS, J. D et al.Cancer research (Baltimore). 1988, Vol 48, Num 22, pp 6597-6602, issn 0008-5472Article

Decreased expression of class II major histocompatibility antigens on monocytes from patients with Hodgkin's diseaseNAGAI, H; FISHER, R. I; COSSMAN, J et al.Journal of leukocyte biology. 1986, Vol 39, Num 3, pp 313-321, issn 0741-5400Article

Bortezomib and gemcitabine in relapsed or refractory Hodgkin's lymphomaMENDLER, J. H; KELLY, J; FRIEDBERG, J. W et al.Annals of oncology. 2008, Vol 19, Num 10, pp 1759-1764, issn 0923-7534, 6 p.Article

Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphomaVOSE, J. M; LINK, B. K; GROSSBARD, M. L et al.Journal of clinical oncology. 2001, Vol 19, Num 2, pp 389-397, issn 0732-183XArticle

Simian virus 40 is present in most united States human mesotheliomas, but it is rarely present in non-Hodgkin's lymphomaRIZZO, P; CARBONE, M; FISHER, S. G et al.Chest. 1999, Vol 116, Num 6, pp S470-S473, issn 0012-3692, SUPConference Paper

CHOP therapy : Has shorter-course therapy had an impact on lymphomas?GAYNOR, E. R; FISHER, R. I.Cancer investigation. 1998, Vol 16, Num 1, pp 26-32, issn 0735-7907Article

Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphomaMILLER, T. P; DAHLBERG, S; CASSADY, J. R et al.The New England journal of medicine. 1998, Vol 339, Num 1, pp 21-26, issn 0028-4793Article

Concurrent phase I trials of intravenous interleukin 6 in solid tumor patients : Reversible dose-limiting neurological toxicitySOSMAN, J. A; ARONSON, F. R; MIER, J et al.Clinical cancer research. 1997, Vol 3, Num 1, pp 39-46, issn 1078-0432Article

Aggressive treatment for postcardiac transplant lymphoproliferationSWINNEN, L. J; MULLEN, G. M; CARR, T. J et al.Blood. 1995, Vol 86, Num 9, pp 3333-3340, issn 0006-4971Article

Phase IB clinical trial of anti-CD3 followed by high-dose bolus interleukin-2 in patients with metastatic melanoma and advanced renal cell carcinoma : clinical and immunologic effectsSOSMAN, J. A; WEISS, G. R; ERNEST, M. L et al.Journal of clinical oncology. 1993, Vol 11, Num 8, pp 1496-1505, issn 0732-183XArticle

Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alfa-2b in advanced renal cell carcinomaATKINS, M. B; SPARANO, J; SOSMAN, J. A et al.Journal of clinical oncology. 1993, Vol 11, Num 4, pp 661-670, issn 0732-183XArticle

Phase II trial of recombinant human interferon α in myelodysplastic syndromesSUCHA NAND; ELLIS, T; MESSMORE, H et al.Leukemia. 1992, Vol 6, Num 3, pp 220-223, issn 0887-6924Article

Cytotoxic synergy of cisplatin with concurrent hydroxyurea and cytarabine : summary of an in vitro model and initial clinical pilot experienceALBAIN, K. S; SWINNEN, L. J; ERICKSON, L. C et al.Seminars in oncology. 1992, Vol 19, Num 3, pp 102-109, issn 0093-7754, SUP9Article

Clinical trials of α-interferon in the treatment of non-Hodgkin's lymphomaGAYNOR, E. R; FISHER, R. I.Seminars in oncology. 1991, Vol 18, Num 5, pp 12-17, issn 0093-7754, SUP7Article